Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study

Figures & data

Table 1 Baseline Demographics and Clinical Characteristics

Characteristics	Working Patients with MDD (N=424)
Age (years)	30.5 ± 11.1
Female sex	267 (63.0)
Marital status
Single	256 (60.4)
Married/living together	156 (36.8)
Divorced/separated	9 (2.1)
Widowed	1 (0.2)
Unknown	2 (0.5)
Urban living area	376 (88.7)
Educational level
Elementary school	5 (1.2)
Middle school	36 (8.5)
High school	44 (10.4)
Junior college	53 (12.5)
University	230 (54.2)
Postgraduate school or above	56 (13.2)
Employment type
Full-time	419 (98.8)
Part-time	5 (1.2)
Time since first MDD diagnosis (years)	1.7 ± 3.4
Current MDE
Duration (weeks)	37.8 ± 73.8
≤4 weeks	110 (25.9)
>4–≤24 weeks	172 (40.6)
>24 weeks	142 (33.5)
No. of prior MDEs^a	1.4 ± 3.3
≥1 relevant comorbidity at baseline	236 (55.7)
≥1 psychiatric comorbidity at baseline	220 (51.9)
Anxiety disorder	165 (38.9)
Sleep disorder	103 (24.3)
Vortioxetine treatment line
First	245 (57.8)
Second	141 (33.3)
Third or later	38 (9.0)
Baseline assessments
SDS total score	16.5 ± 7.0
SDS work/school score^b	5.9 ± 2.7
SDS social life score	5.5 ± 2.5
SDS family life/home responsibilities score	5.0 ± 2.8
PHQ-9 total score	15.9 ± 6.0
HAM-D17 total score^c	18.7 ± 6.0
CGI-S score	4.2 ± 0.9
PDQ-D score^d	37.2 ± 17.5
GAD-7 total score^d	12.0 ± 5.3

Notes: Data are mean ± standard deviation or n (%). ^an=421. ^bn=405. ^cn=422. ^dn=423.

Abbreviations: CGI-S, Clinical Global Impressions–Severity of Illness scale (range, 1–7); GAD-7, Generalized Anxiety Disorder 7-item scale (range, 0–21); HAM-D17, 17-item Hamilton Depression Rating Scale (range, 0–54); MDD, major depressive disorder; MDE, major depressive episode; PDQ-D, Perceived Deficits Questionnaire–Depression (range, 0–80); PHQ-9, 9-item Patient Health Questionnaire (range, 0–27); SDS, Sheehan Disability Scale (range, 0–30).

Figure 1 Vortioxetine dosing in working patients with major depressive disorder over the 6-month study period (n=424).

Note: Cited one-decimal-place values may not sum to 100% because of rounding.

Figure 2 Adjusted mean (SE) change from baseline to weeks 8 and 24 for SDS total and domain scores (mixed-model repeated measures analysis).

Note: P<0.001 for all changes from baseline.

Abbreviations: SDS, Sheehan Disability Scale; SE, standard error.

Figure 3 Change in level of functional impairment over time in working patients with MDD treated with vortioxetine.

Notes: Sheehan Disability Scale total score ranges for levels of functional impairment: minimal (0–5), mild (6–11), moderate (12–20), severe (21–30). Cited one-decimal-place values may not sum to 100% because of rounding.

Figure 4 Adjusted mean (SE) change from baseline to weeks 8 and 24 for SDS total score by (A) vortioxetine treatment line and (B) duration of MDD (mixed-model repeated measures analysis).

Note: P<0.001 for all changes from baseline.

Abbreviations: SDS, Sheehan Disability Scale; MDD, major depressive disorder; SE, standard error.

Figure 5 Adjusted mean (SE) change from baseline to weeks 8 and 24 for PHQ-9, HAM-D17, CGI-S, GAD-7, and PDQ-D scores (mixed-model repeated measures analysis).

Note: P<0.001 for all changes from baseline.

Abbreviations: CGI-S, Clinical Global Impressions–Severity of Illness scale; GAD-7, Generalized Anxiety Disorder 7-item scale; HAM-D17, 17-item Hamilton Depression Rating Scale; PDQ-D, Perceived Deficits Questionnaire–Depression; PHQ-9, 9-item Patient Health Questionnaire; SE, standard error.

Table 2 Summary of AEs Reported in Adhering Working Patients During the Study

	Adhering Working Patients (N=424)
Patients with at least one treatment-related AE	169 (39.9)
Patients with serious AE	14 (3.3)
Treatment-related serious AE	1 (0.2)
Treatment-related AEs with incidence of ≥2% of patients
Nausea	79 (18.6)
Dizziness	13 (3.1)
Pruritus	10 (2.4)

Notes: Data are n (%). Adhering patients initiated treatment with vortioxetine and remained on treatment at all follow-up visits.

Abbreviation: AE, adverse event.

Data Sharing Statement

The authors confirm that the data supporting the findings of this study are available within the article. The authors may be contacted for further data sharing.